Robert E. Dudley - 09 Sep 2021 Form 4 Insider Report for Clarus Therapeutics Holdings, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Steven A. Bourne, attorney-in-fact
Issuer symbol
N/A
Transactions as of
09 Sep 2021
Net transactions value
$0
Form type
4
Filing time
13 Sep 2021, 20:31:00 UTC
Next filing
14 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRXT Common Stock Award $0 +4,566 $0.000000 4,566 09 Sep 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer.